Key Highlights

  • Total Revenue was US$120.3 million, up from US$17.2 million a year earlier.
  • Net sales of Ryoncil were US$115.2 million in its first full year of US launch.
  • The net loss narrowed 44% to US$57.5 million.
  • More than 50 US sites have been onboarded since launch.

What do Mesoblast's (ASX:MSB) FY26 results show about its transition from a development-stage company to a commercial one? In results reported on 26 to 27 August 2026 for the year ended 30 June 2026, the cell-therapy group recorded total revenue of US$120.3 million, up from US$17.2 million a year earlier, with net sales of its Ryoncil therapy of US$115.2 million. The net loss narrowed 44% to US$57.5 million. The result shows early commercial traction, but the company still reports a loss, carries borrowings and depends on trial and regulatory milestones.

The central development: Ryoncil becomes a commercial product

Ryoncil (remestemcel-L) is approved in the United States for paediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD), a serious complication of stem-cell transplantation. FY26 was the first full year of its US launch. Net product sales were US$115.2 million after a 13.4% gross-to-net adjustment, which is the deduction from list price for rebates and similar items. Gross Profit was US$103.6 million as reported, or US$109.7 million excluding amortisation. The company said more than 50 US sites have been onboarded since launch.

The second-half net loss was US$17.3 million, compared with a full-year loss of US$57.5 million, indicating the loss was concentrated in the first half.

Financial position

Revenue: US$120.3 million, up from US$17.2 million.

Net loss: US$57.5 million, down 44% from US$102.1 million.

Cash: US$103 million at 30 June 2026.

Borrowings: about US$119.2 million in total (US$10.6 million current and US$108.6 million non-current).

During the period, Mesoblast entered a five-year, US$125.0 million non-dilutive Credit line, which replaced two higher-cost facilities. Cash of US$103 million against that Burn Rate and the borrowings means the path to sustained cash generation depends on continued Ryoncil growth and on controlled research spending. R&D expense rose by US$39.7 million after adjusting for a US$23.0 million inventory benefit in the prior period, which shows the company is investing heavily in its pipeline.

The company gave no formal financial guidance in the material reviewed.

Growth plans: adults and other indications

The largest identified opportunity is extending Ryoncil's label to adults. Mesoblast plans to pursue adult use both as third-line therapy and with ruxolitinib as second-line therapy, and it cites the adult market as about three times the size of the paediatric one. Data from February 2026 showed 76% Day 100 survival in adolescents and adults treated third-line, compared with a historical range of 20% to 30%. These are company-reported results from a specific dataset and do not replace regulatory approval. The adult second-line registration trial is enrolling, and up to 40 US sites are expected to be activated this year.

The pipeline also includes:

Chronic low back pain (rexlemestrocel-L): the Phase 3 trial has treated 350 patients, above the 300 planned.

Heart failure with a left ventricular assist device (LVAD): Mesoblast received a Biologics License Application (BLA) filing number and requested a modular review, to be discussed with the US Food and Drug Administration (FDA) next quarter.

Duchenne muscular dystrophy: the FDA cleared an investigational new drug application for a registrational trial of Ryoncil in ambulatory children aged 5 to 9.

Sector and competitive position

Mesoblast operates in cell and regenerative medicine, where regulatory approval is difficult and Manufacturing is complex. Its position as holder of an approved allogeneic mesenchymal cell therapy is a notable differentiator, since few such products have reached the market. In SR-aGvHD, the company competes with existing treatments such as ruxolitinib and other approved and investigational agents, so adult uptake would depend on trial results and clinician adoption. The low back pain and heart failure programs address very large markets, which could mean greater commercial potential but also higher trial cost, longer timelines and more competition.

Material risks

Concentration: nearly all revenue comes from one product in one indication, so any disruption to demand, reimbursement or manufacturing would be material.

Clinical and regulatory outcomes: the adult trial, the back pain Phase 3 and the LVAD pathway could Fail or be delayed, and the FDA may not accept the proposed modular review.

Pricing and reimbursement: the 13.4% gross-to-net adjustment could change as payer dynamics evolve.

Rising R&D spend: larger trials increase costs before revenue arrives.

Competition: other therapies may reduce uptake or set a higher benchmark.

What to watch next

According to the company, the near-term items are the FDA discussion on the LVAD modular BLA review next quarter, activation of up to 40 US sites for the adult registration trial later this year, and the top-line back pain Phase 3 data in mid-2027. Sales trends for Ryoncil each quarter will be the clearest read on commercial progress.